| | | | | | | | | | |
|
|
|
|
| Dockets Entered
On December 17, 2007
|
|
|
|
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
|
|
| 1995S-0316
|
| 75-Day Premarket Notifications for New Dietary Ingredients
|
|
|
|
|
| 2006P-0394
|
| Revise the labeling requirements for eggs sold in the United States
|
|
|
|
|
| 2006P-0422
|
| Refrain from approval of any ANDA for metoprolol succinate extended release 100 mg and 200 mg tablets subsequent to ANDA 76-640 from KV Pharmaceutical
|
|
|
|
|
| 2007N-0200
|
| Agency Information Collection Activities; Proposed Collection; Comment Request; Comment Request; Health and Diet Survey
|
|
|
|
|
| 2007N-0262
|
| Use of Ozone-Depleting Substances; Removal of Essential-Use Designation (Epinephrine)
|
|
|
|
|
| 2007N-0356
|
| BEHIND THE COUNTER AVAILABILITY OF CERTAIN DRUGS; Public Meeting
|
|
|
|
|
| 2007P-0235
|
| Change the labeling requirements for eggs sold in the United States
|
|
|
|
|
| 2007P-0400
|
| Formally ban unnaturally synthesized fluoride compounds sold for consumption through oral ingestion
|
|
|
|
|
| 2007P-0479
|
| Require that all print and electronic advertisements, including Internet advertisements, for implantable devices such as knee, hip heart valves, cosmetic implants, and other devices
|
|
|
|
|
| 2007V-0048
|
| Laser Light Show
|
|
| |
|
| 1995S-0316
|
| 75-Day Premarket Notifications for New Dietary Ingredients
|
|
|
|
|
| RPT 417
|
| Mitsibushi Gas Chemical Company
|
| Vol #:
|
| 330
|
|
|
|
|
| RPT 418
|
| ACM-Texas, LLC
|
| Vol #:
|
| 330
|
|
|
|
|
| RPT 419
|
| BHN Co., Ltd
|
| Vol #:
|
| 330
|
|
|
|
|
| 2006P-0394
|
| Revise the labeling requirements for eggs sold in the United States
|
|
|
|
|
| C 510
|
| M. Medina
|
| Vol #:
|
| 14
|
|
|
|
|
| C 511
|
| K. Ozkum
|
| Vol #:
|
| 14
|
|
|
|
|
| 2006P-0422
|
| Refrain from approval of any ANDA for metoprolol succinate extended release 100 mg and 200 mg tablets subsequent to ANDA 76-640 from KV Pharmaceutical
|
|
|
|
|
| PDN 1
|
| FDA/CDER
|
| Vol #:
|
| 1
|
|
|
|
|
| 2007N-0200
|
| Agency Information Collection Activities; Proposed Collection; Comment Request; Comment Request; Health and Diet Survey
|
|
|
|
|
| N 2
|
| FDA
|
| Vol #:
|
| 1
|
|
|
|
|
| 2007N-0262
|
| Use of Ozone-Depleting Substances; Removal of Essential-Use Designation (Epinephrine)
|
|
|
|
|
| C 9
|
| D. Warren
|
| Vol #:
|
| 1
|
|
|
|
|
| 2007N-0356
|
| BEHIND THE COUNTER AVAILABILITY OF CERTAIN DRUGS; Public Meeting
|
|
|
|
|
| C 8
|
| American Society of Health-System Pharmacists
|
| Vol #:
|
| 2
|
|
|
|
|
| C 9
|
| Medco Health Solutions, Inc.,
|
| Vol #:
|
| 2
|
|
|
|
|
| 2007P-0235
|
| Change the labeling requirements for eggs sold in the United States
|
|
|
|
|
| LET 2
|
| FDA/CFSAN/ONLDS
|
| Vol #:
|
| 4
|
|
| |
|
| 2007P-0400
|
| Formally ban unnaturally synthesized fluoride compounds sold for consumption through oral ingestion
|
|
|
|
|
| C 4
|
| R. Sauerheber
|
| Vol #:
|
| 1
|
|
|
|
|
| 2007P-0479
|
| Require that all print and electronic advertisements, including Internet advertisements, for implantable devices such as knee, hip heart valves, cosmetic implants, and other devices
|
|
